Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.

ABSTRACT:

Objective

To assess the association between use of sodium-glucose co-transporter 2 (SGLT2) inhibitors and risk of serious renal events in data from routine clinical practice.

Design

Cohort study using an active comparator, new user design and nationwide register data.

Setting

Sweden, Denmark, and Norway, 2013-18.

Participants

Cohort of 29 887 new users of SGLT2 inhibitors (follow-up time: dapagliflozin 66.1%; empagliflozin 32.6%; canagliflozin 1.3%) and 29 887 new users of an active comparator, dipeptidyl peptidase-4 inhibitors, matched 1:1 on the basis of a propensity score with 57 variables. Mean follow-up time was 1.7 (SD 1.0) years.

Exposures

SGLT2 inhibitors versus dipeptidyl peptidase-4 inhibitors, defined by filled prescriptions and analysed accor

SUBMITTER: Pasternak B 

PROVIDER: S-EPMC7188014 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature